Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disproxil

- PMLiVE

Rivals look to put pressure on Sanofi’s Lantus

Novo Nordisk and Lilly claim clinical benefitsover top-selling diabetes drug

Sanofi reception

Sanofi and Amgen poised for cholesterol drug sales

Praluent to be assessed by FDA advisory committee later this week

- PMLiVE

Novo brings Xultophy to third European market

Launches diabetes combination of Tresiba-Victoza in the UK

- PMLiVE

Sanofi rare disease drug a breakthrough, says FDA

Regulator awarded the status to olipudase alfa for metabolic disorder

- PMLiVE

IQWiG unimpressed with Tresiba for children

German cost watchdog says Novo’s insulin may in fact cause more harm in certain patients

- PMLiVE

Sanofi pays $245m for FDA priority review voucher

PRV reduces review time from ten to six months

Lilly backs Bluetooth insulin device and app firm

Invests in San Diego-based medical device company Companion Medical

Sanofi reception

Sanofi licenses cardiovascular therapy in South Korea

Phase III drug comes from Swedish company NeuroVive

Sanofi appoints Suresh Kumar as EVP of external affairs

He previously worked for the Clinton Foundation focused on Sub-Saharan Africa

EU flag

Three cancer immunotherapies amongst new CHMP approvals

BMS’ Evotaz also amongst eight new medicine recommendations

Sanofi reception

Sanofi says sarilumab filing for arthritis on track

Looks likely to be filed before the end of the year

- PMLiVE

AZ to screen 80,000 patients for genetic disease traits

Will work with Montreal Heart to investigate cardiovascular and diabetic signals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links